echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Nature Sub-Journal: Nanoparticles can target white blood cells that cause acute lung inflammation

    Nature Sub-Journal: Nanoparticles can target white blood cells that cause acute lung inflammation

    • Last Update: 2022-01-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The COVID-19 pandemic highlights the devastating effects of acute lung inflammation (ALI), which is part of acute respiratory distress syndrome (ARDS), and ARDS is the main cause of death from COVID-19
    .


    A potential new route for diagnosis and treatment of ARDS comes from studying neutrophils-white blood cells are responsible for detecting and eliminating harmful particles in the body-distinguishing the surface structure of the material's absorption material, which is conducive to the absorption of particles, showing "protein coagulation," University of Pennsylvania A new study from the Perelman School of Medicine shows


    Researchers investigated how neutrophils distinguish between destroyed bacteria and other compounds in the blood, such as cholesterol particles
    .


    They tested a library of 23 different protein-based nanoparticles in mice with ALI, revealing a set of "rules" for predicting neutrophil uptake


    "We hope to use the existing functions of neutrophils to identify and eliminate invaders to inform how to design a'Trojan horse' nanoparticles.
    Overactive neutrophils will ingest and provide treatment to relieve ALI and ARDS.

    "Said Dr.


    Jacob Myerson, the first author of the study and a postdoctoral researcher in the Department of Systems Pharmacology and Translational Therapy


    Acute respiratory failure and acute respiratory distress syndrome are life-threatening forms of respiratory failure with high morbidity and mortality
    .


    Before COVID-19, there were 190,000 ARDS cases and 75,000 deaths in the United States each year.


    To solve acute respiratory distress syndrome and other medical problems, researchers at the University of Pennsylvania and elsewhere have been using nanoparticles to concentrate drugs in injured or diseased organs
    .


    Such nanoparticles are also used in gene therapy and immunotherapy


    This group of scientists pointed out that although there is still a long way to go in the development of a feasible treatment for ALI/ARDS that uses nanoparticles to provide treatment through neutrophils, this research represents a step forward in understanding the status and function of the immune system.
    An important step
    .

    "Now that we have determined that neutrophils will patrol nanoparticles with agglutinin, our next step is to understand how and why other microorganisms, such as viruses, these rigid and symmetrical microorganisms have evolved to avoid neutrophils.
    Yes," said senior author Dr.
    Jacob Brenner, an associate professor of pulmonary medicine in the Department of Pulmonary Disease, Allergy, and Intensive Care
    .


    "With this knowledge, we can continue to use this unique combination of materials science and engineering to create specific disease treatments for more advanced and complex pathologies


    Article title

    Supramolecular arrangement of protein in nanoparticle structures predicts nanoparticle tropism for neutrophils in acute lung inflammation

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.